

Docket No. 216432US0X DIV



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Kokichi KIKUCHI, et al.

SERIAL NO: 10/038,899

GAU: 1636

FILED: January 8, 2002

EXAMINER: Kaushal, S.

FOR: PEPTIDE CAPABLE OF INDUCING IMMUNE RESPONSE TO HUMAN GASTRIC CANCER AND AGENT FOR PREVENTING OR TREATING HUMAN GASTRIC CANCER, CONTAINING THE PEPTIDE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Vincent K. Shier, Ph.D.
Registration No. 50,552

05/18/2004 TBESHAH1 00000002 10038899

02 FC:1806

180.00 OP

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)



Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 216432US0X DIV		SERIAL NO. 10/038,899	
LIST OF REFERENCES CITED, BY APPLICANT				APPLICANT Kokichi KIKUCHI, et al.			
				FILING DATE January 8, 2002		GROUP 1636	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AU	S. A. ROSENBERG, M.D., Ph.D., et al., "USE OF TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN THE IMMUNOTHERAPY OF PATIENTS WITH METASTATIC MELANOMA", The New England Journal of Medicine, Vol. 319, No. 25, Dec. 22, 1988, pp. 1676-1680					
	AV	U. TOH, et al., "LOCOREGIONAL CELLULAR IMMUNOTHERAPY FOR PATIENTS WITH ADVANCED ESOPHAGEAL CANCER", Clinical Cancer Research, Vol. 6, Dec. 2000, pp. 4663-4673					
	AW	M. DUDLEY, et al., "CANCER REGRESSION AND AUTOIMMUNITY IN PATIENTS AFTER CLONAL REPOPULATION WITH ANTITUMOR LYMPHOCYTES", SCIENCE, Vol. 298, Oct. 25, 2002, pp. 850-854					
	AX	Y. WADA, et al., "IN VITRO PROLIFERATION AND THE CYTOTOXIC SPECIFICITY OF A CRYOPRESERVED CYTOTOXIC T CELL CLONE REACTING AGAINST HUMAN AUTOLOGOUS TUMOR CELLS", Journal of Immunological Methods, 154, (1992), pp. 235-243					
	AY	Y. WADA, et al., "BREFELDIN A BLOCKS THE CYTOTOXICITY OF T CELL RECEPTOR α/β AND γ/δ CYTOTOXIC T LYMPHOCYTE CLONES REACTING AGAINST HUMAN AUTOLOGOUS CANCER CELLS", Jpn. J. Cancer Res., 84, August 1993, pp. 906-913					
	AZ	T. YASOSHIMA, M.D., et al., "THE MECHANISM OF HUMAN AUTOLOGOUS GASTRIC SIGNET RING CELL TUMOR REJECTION BY CYTOTOXIC T LYMPHOCYTES IN THE POSSIBLE CONTEXT OF HLA-A31 IN MOLECULE", Cancer Supplement, Vol. 75, No. 6, March 15, 1995, pp. 1484-1489				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							